Last reviewed · How we verify
Laserphyrin (TALAPORFIN)
Laserphyrin (generic name: TALAPORFIN) is a talaporfin Small molecule drug developed by Meiji Seika Pharm. It is currently FDA-approved (first approved 2015) for Malignant tumor of lung, Primary malignant neoplasm of brain.
Laserphyrin, also known as talaporfin sodium, is a small molecule used in the treatment of various conditions, including Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, and certain types of cancer. It has been studied in clinical trials using different interventions, including the placement of a device in the prostate urethra and transurethral illumination with light emitting diodes.
At a glance
| Generic name | TALAPORFIN |
|---|---|
| Sponsor | Meiji Seika Pharm |
| Drug class | talaporfin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Malignant tumor of lung
- Primary malignant neoplasm of brain
Common side effects
Key clinical trials
- Novel Treatment for Port Wine Stain Birthmarks (PHASE1)
- A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (PHASE2)
- Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases (PHASE3)
- Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas (PHASE1)
- A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) (PHASE3)
- Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma (PHASE2)
- Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PHASE1)
- Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Laserphyrin CI brief — competitive landscape report
- Laserphyrin updates RSS · CI watch RSS
- Meiji Seika Pharm portfolio CI
Frequently asked questions about Laserphyrin
What is Laserphyrin?
What is Laserphyrin used for?
Who makes Laserphyrin?
What is the generic name of Laserphyrin?
What drug class is Laserphyrin in?
When was Laserphyrin approved?
What development phase is Laserphyrin in?
Related
- Drug class: All talaporfin drugs
- Manufacturer: Meiji Seika Pharm — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Malignant tumor of lung
- Indication: Drugs for Primary malignant neoplasm of brain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing